Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess
PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of
CHS-1701 (Coherus pegfligrastim) or 6mg SC dose of Neulasta (pegfilgrastim) given during each
period.